BiotechTube
MLAB Biosciences

MLAB Biosciences

San Diego, United States· Est.
mlabbiosciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

MLAB Biosciences is a private, pre-clinical stage biotech founded in 2016 and based in San Diego, California. The company's core asset is the DIRECT™ (Display Integrated Rational Engineering for the Creation of Therapeutics) platform, an antibody discovery and engineering engine designed to generate novel biologics. With a leadership team and advisory board featuring prominent neuromuscular disease experts, MLAB is positioned to tackle challenging targets in muscular dystrophy and beyond, though it remains in the early, pre-revenue stage of development.

Muscular DystrophyNeuromuscular Diseases

Technology Platform

DIRECT™ (Display Integrated Rational Engineering for the Creation of Therapeutics) - A proprietary platform for the discovery and engineering of novel antibody-based biologics.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The significant unmet need in muscular dystrophy creates a large market for novel, mutation-agnostic therapies.
Success in this initial focus could validate the DIRECT™ platform for broader application across other disease areas requiring complex biologics, such as oncology or autoimmune disorders.

Risk Factors

As an early-stage biotech, MLAB faces high technical risk that its platform will yield a viable drug candidate, alongside the substantial clinical development and regulatory risks inherent in bringing a new biologic to market.
The company is also dependent on securing continued funding in a competitive capital environment to advance its programs.

Competitive Landscape

The muscular dystrophy therapeutic space is competitive, featuring large pharma (e.g., Roche, Pfizer, Sarepta) and biotech companies pursuing gene therapies, exon-skipping, and other modalities. MLAB's differentiation hinges on its antibody-based approach and the potential of its DIRECT™ platform to discover novel biologics against challenging targets.

More companies in Biologics / Biosimilars →More companies in United States →